Antithrombotic Monotherapy or Combination Therapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Meta‐Analysis of Randomized Trials
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.125.041422 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Rohin K Reddy und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute Imperial College London London UK. Hauptthemen laut MEDLINE: Atrial Fibrillation, Coronary Artery Disease, Fibrinolytic Agents, Anticoagulants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
In patients with atrial fibrillation and stable coronary artery disease, guidelines recommend oral anticoagulation monotherapy after periods on dual antithrombotic therapy. These recommendations are based on evidence from prematurely terminated randomized controlled trials that were underpowered for bleeding and mortality end points. New data are available, so we conducted a systematic review and meta‐analysis to pool the totality of randomized evidence.
Methods
This investigation was preregistered on International Prospective Register of Systematic Reviews (CRD42024590457). Systematic searches and data extraction were performed independently and in duplicate for randomized controlled trials enrolling patients with atrial fibrillation and stable coronary artery disease that reported clinical end points. The prespecified coprimary end points were major bleeding and all‐cause death. Prespecified secondary outcomes included all bleeding, cardiovascular death, noncardiovascular death, myocardial infarction, stroke, the composite of net adverse cardiovascular events and coronary revascularization. End point data were pooled using fixed and random effect models, to generate hazard ratios (HR) and relative risks and corresponding 95% CIs.
Results
Four randomized controlled trials enrolling 4092 patients were eligible, with 2049 randomized to monotherapy and 2043 randomized to dual therapy. Monotherapy reduced the hazard of major bleeding by 41% (HR, 0.59 [95% CI, 0.44–0.79], P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Heart and Lung Institute Imperial College London London UK.
- Nuffield Department of Population Health University of Oxford Oxford UK.
- Department of Cardiology, Angiology and Respiratory Medicine Heidelberg University Hospital Heidelberg Germany.
- Liverpool Centre for Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart & Chest Hospital Liverpool UK.
- Danish Center for Health Services Research, Department of Clinical Medicine Aalborg University Aalborg Denmark.
- Division of Cardiology University of California San Francisco CA USA.
ORCID-Profile: Rohin K Reddy, Gregory Y H Lip, James P Howard, Yousif Ahmad
Zitieren
APA
Reddy, R. K., Koeckerling, D., Lip, G. Y. H., Howard, J. P., & Ahmad, Y. (2025). Antithrombotic Monotherapy or Combination Therapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Meta‐Analysis of Randomized Trials. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.041422
Vancouver
Reddy RK, Koeckerling D, Lip GYH, Howard JP, Ahmad Y. Antithrombotic Monotherapy or Combination Therapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Meta‐Analysis of Randomized Trials. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.041422
BibTeX
@article{Reddy2025,
author = {Reddy, Rohin K and Koeckerling, David and Lip, Gregory Y H and Howard, James P and Ahmad, Yousif},
title = {Antithrombotic Monotherapy or Combination Therapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Meta‐Analysis of Randomized Trials},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.125.041422}
}
EUVIMED